This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MGEN Miragen Therapeutics (MGEN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrendsBuy This Stock About Miragen Therapeutics Stock (NASDAQ:MGEN) 30 days 90 days 365 days Advanced Chart Remove Ads Get Miragen Therapeutics alerts:Sign Up Key Stats Today's Range$11.90▼$12.6850-Day Range$14.34▼$23.0152-Week Range$4.66▼$34.05Volume1.12 million shsAverage Volume134,027 shsMarket Capitalization$49.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMiragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.Read More… Remove Ads Receive MGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Miragen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MGEN Stock News HeadlinesAmgen and MediLink to collaborate on SCLC combination therapyOctober 10, 2024 | msn.comWhy Biotech Giant Amgen Stands A Chance Of Taking On Novo, Lilly In ObesityAugust 7, 2024 | msn.comAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.April 4, 2025 | Paradigm Press (Ad)AMGN Earnings: Amgen Stock Down on Mixed Q2 ResultsAugust 7, 2024 | msn.comAmgen Undercuts Its Buy Point On Mixed Second-Quarter ReportAugust 6, 2024 | msn.comMiragen Therapeutics is about to announce earnings — here's what Wall Street expectsMay 7, 2024 | markets.businessinsider.comViridian Therapeutics Inc (VRDN)January 30, 2024 | investing.comSee More Headlines MGEN Stock Analysis - Frequently Asked Questions How were Miragen Therapeutics' earnings last quarter? Miragen Therapeutics, Inc. (NASDAQ:MGEN) announced its quarterly earnings data on Tuesday, November, 10th. The medical research company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.03. Miragen Therapeutics had a negative net margin of 1,393.50% and a negative trailing twelve-month return on equity of 141.66%. What other stocks do shareholders of Miragen Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Miragen Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Nokia Oyj (NOK), VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX) and Pfizer (PFE). Company Calendar Last Earnings11/10/2020Today4/04/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Laboratories Sub-IndustryN/A Current SymbolNASDAQ:MGEN CIK1590750 Webwww.signalgenetics.com Phone720-643-5200FaxN/AEmployees45Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($20.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,870,000.00 Net Margins-1,393.50% Pretax MarginN/A Return on Equity-141.66% Return on Assets-88.74% Debt Debt-to-Equity Ratio0.20 Current Ratio4.23 Quick Ratio4.23 Sales & Book Value Annual Sales$4.46 million Price / Sales11.08 Cash FlowN/A Price / Cash FlowN/A Book Value$6.78 per share Price / Book1.87Miscellaneous Outstanding Shares3,908,000Free FloatN/AMarket Cap$49.44 million OptionableNot Optionable Beta1.66 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:MGEN) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Miragen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Miragen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.